Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Enanta Pharmaceuticals (ENTA) Leases (2019 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Leases for 7 consecutive years, with $37.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 6.73% year-over-year to $37.0 million, compared with a TTM value of $37.0 million through Dec 2025, down 6.73%, and an annual FY2025 reading of $37.5 million, down 7.65% over the prior year.
  • Leases was $37.0 million for Q4 2025 at Enanta Pharmaceuticals, down from $37.5 million in the prior quarter.
  • Across five years, Leases topped out at $41.2 million in Q2 2024 and bottomed at $4.7 million in Q3 2021.
  • Average Leases over 5 years is $26.1 million, with a median of $23.8 million recorded in 2022.
  • The sharpest move saw Leases crashed 32.89% in 2021, then surged 400.42% in 2022.
  • Year by year, Leases stood at $18.8 million in 2021, then increased by 24.99% to $23.5 million in 2022, then decreased by 9.33% to $21.3 million in 2023, then surged by 85.88% to $39.7 million in 2024, then decreased by 6.73% to $37.0 million in 2025.
  • Business Quant data shows Leases for ENTA at $37.0 million in Q4 2025, $37.5 million in Q3 2025, and $38.2 million in Q2 2025.